pressurized metered dose inhalers (pMDIs) are an inexpensive, frontline technology for the treatment of asthma and other pulmonary diseases. Some patients, however, find it difficult to achieve the coordination needed to successfully use a pMDI. Along with novel breath-actuated pMDIs, add-on devices, such as spacers and/or valved holding chambers (VHCs), eliminate the requirement to coordinate device actuation with inhalation and make conventional pMDI technology more effective for a broader spectrum of patients. Globally, the incidence of asthma and chronic obstructive pulmonary disease (COPD) continues to rise, and the use of add-on devices is increasing proportionately. This increasing use is reflected in a new, draft United States Pharmacopeia (USP) chapter, issued January 2014, which specifies new test methods for pMDIs with add-on devices (1).

Mark Copley, sales director of Copley Scientific, provides expert insight on why add-on devices are used, how these devices impact drug delivery with a pMDI, and the tests that can be applied to representatively characterize pMDI performance when an add-on device is required.

Add-on devices and the impact on drug delivery

What is an add-on device and why is it used?

Copley: The ‘go to’ technology for treating asthma and COPD, pMDIs are small, inexpensive, convenient to use and suitable for the delivery of a wide range of drugs. When actuated, these products use a propel-
When a patient uses a pMDI without an add-on device, the drug particles are inhaled almost instantaneously as the formulation is aerosolized. Providing that the patient’s technique is correct, the size of particles inhaled will, therefore, be relatively well defined. Delivered particle size is a function of the device design (actuator and canister) and the properties of the formulation, which includes the propellant.

In contrast, when an add-on device is used, the patient inhales drug from a reservoir of aerosolized particles. The additional dead volume provided by the add-on device not only provides an opportunity for aerosol expansion, but also particle impaction, settling, and/or electrostatic deposition, within the add-on device. This means that the particle size distribution of the aerosol cloud made available to the patient may change considerably ahead of inhalation. Certain sized particles may be preferentially retained in the spacer and the size distribution of particles received by the patient may now differ from that delivered by the pMDI.

Variability in the drug-delivery process is also introduced by the fact that the device actuation may be completely coordinated with the inhalation maneuver, or completely uncoordinated, depending on the technique adopted by the individual user.

**Testing pMDI performance**

What tests are recommended in the proposed USP chapter and how do they differ from the standard tests used for pMDIs?

**Copley:** The general pharmacopeia tests for the assessment of pMDI performance and for quality control (QC) center on the measurement of two parameters—delivered dose uniformity (DDU) and aerodynamic particle size distribution (APSD). In DDU testing, the pMDI is actuated into a dose uniformity sampling apparatus (DUSA) that captures the emitted formulation on a filter. Subsequent analysis of the captured dose, usually by high-performance liquid chromatography (HPLC), reveals how much active ingredient is present.

**Copley:** Variability in the drug-delivery process is also introduced by the fact that the device actuation may be completely coordinated with the inhalation maneuver, or completely uncoordinated, depending on the technique adopted by the individual user.

**APSD measurements** are made using a multistage cascade impactor. This instrument size fractionates an emitted dose on the basis of particle inertia, which is a direct function of aerodynamic particle size. Chemical analysis of the collected, sized samples enables the determination of an APSD specifically for the active ingredient.

Because the particle size delivered by a pMDI is generally unaffected by the patient’s inhalation profile, the test conditions applied for these analyses have been set on the basis of convenience. The first cascade impactors used in orally inhaled product analysis were developed for air sampling and originally designed and calibrated to operate at 1 SCFM (standard cubic foot per minute). This value directly translates to the 28.3 L/min used for APSD measurement today for pMDIs. The same figure has, therefore, been adopted for DDU testing.

The tests set out in the new, draft chapter for testing pMDIs with add-on devices are based on experience gained in Canada over the past 10 years following the publication of a standard for testing by Health Canada. The methods reflect that, as with a nebulizer, the amount of drug received by the patient with this type of set-up will be influenced by the inhalation profile of the user. The tests in the new chapter, therefore, call for the application of specific breathing profiles during DDU testing to reflect the physiology of the intended user (see Table 1).

In DDU testing for pMDIs with add-on devices, the combined product is actuated into a filter housing, thereby collecting the dose in much the same way as a DUSA is used for standard

### Table 1: Breathing simulator specification for characterizing pressurized metered dose inhalers with spacers and valved holding chambers (1).

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Pediatric</th>
<th>Adult</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Neonate</td>
<td>Infant</td>
</tr>
<tr>
<td>Tidal volume (mL)</td>
<td>25</td>
<td>50</td>
</tr>
<tr>
<td>Frequency (min⁻¹)</td>
<td>40</td>
<td>30</td>
</tr>
<tr>
<td>Inspiratory/expiratory ratio</td>
<td>1:3</td>
<td>1:3</td>
</tr>
<tr>
<td>Minute volume (mL)</td>
<td>1000</td>
<td>1500</td>
</tr>
</tbody>
</table>

**Fit for the Lung? By Jon Faulkes and Emma J Mickley, Aesica Pharmaceuticals**

The key to successful delivery of an API to the lung is the generation of a particle that is sufficiently small to be delivered to the lung. In traditional asthma dry powder inhaler, the micronized API with a mass median diameter of between 1.1 μm to 5 μm would be blended with a milled carrier material, such as lactose, and filled into a capsule or device. Upon inhalation, the API particle detaches from the lactose carrier and travels through the respiratory system until it impacts on the surface of the lung. Although used for decades, this approach is far from efficient because of the varied particle size distribution produced as well as the disruption caused to the surface chemistry of the API and carrier by the micronization and milling processes. In this article, the authors discuss methods of creating engineered particles for inhaled drug delivery and the advantages of particle engineering.

To read this article in its entirety, visit [PharmTech.com/Aesica_FitfortheLung](PharmTech.com/Aesica_FitfortheLung)
**Special Report: pMDI Testing**

pMDI testing. However, a patient relevant breathing profile is applied during testing, rather than a constant 28.3 L/min air flow rate. Furthermore, tests are carried out to measure the efficiency of the valve, in the case of VHCs, by comparing the dose received when use is coordinated and uncoordinated with device actuation.

Performance is optimal and directly comparable with a pMDI without an add-on device, if the patient inhales as the device is actuated. This is termed ‘coordinated use.’ In contrast, the worst-case scenario, in terms of performance, is if actuation coincides with exhalation, (i.e., ‘uncoordinated use’). Using a suitable breathing simulator, testing can be carried out under both of these conditions to provide a ratio of drug delivered and hence the efficiency of the valve. For spacers (without valve), testing for co-ordinated use is all that is required. When testing spacers/VHCs with face-masks, these are generally removed, and testing is performed using the integral mouthpiece.

Cascade impactors operate at a constant flow rate so breathing simulators are not applied during APSD measurement. Rather, testing is carried out at a constant flow rate broadly representative of the patient population within the constraints of calibrated commercial impactor performance. The next generation impactor (NGI), which has a calibrated flow rate range of 15 to 100 L/min, is a popular choice for this aspect of testing although other cascade impactors can be used. The particle size range of interest for inhalation to the lung is usually taken as sub-five micron, and this is reflected in the tests that recommend comparison of the sub-five-micron dose (i.e., the emitted fine particle mass) with and without an add-on device.

As with DDU testing, the method specified for APSD measurement has been modified to assess the potential impact of coordinated and uncoordinated use. Testing is carried out with impactor sampling starting after a two-second time delay. This delay provides time for the particle size distribution to evolve inside the VHC and directly quantifies the impact of uncoordinated use in terms of the dose that is likely to deposit in the lung. Testing after five and 10 seconds provides further insight into the residence behavior of the aerosol within the add-on device and is also recommended (5).

Is new equipment needed to test in accordance with the revised USP chapter?

**Copley:** For a laboratory working solely on pMDI technology, it may be that new equipment will be required given that the new draft chapter calls for the application of breathing profiles during testing. However, breathing simulator technology has advanced considerably in the last decade, and cost-effective, compact models are increasingly a standard piece of inhaled product testing equipment.

The Copley Scientific BRS breathing simulator range, for example, includes a number of models specifically tailored to the testing of different orally inhaled products. These systems enable the user to:

- Apply different wave patterns (e.g., square, sinusoidal, triangular, or user defined)
- Alter tidal volume (i.e., the volume of each inhalation and/or exhalation)
- Separately vary the duration of inhalation and exhalation, if required (inspiratory/expiratory ratio)
- Introduce a delay after inhalation and/or exhalation
- Control the number of breathing cycles during each test
- Commence the breathing cycle at the beginning of the inhalation or exhalation maneuver.

The availability of such flexible systems is supporting the application of breathing simulators beyond the scope of the pharmacopeial test methods to more generally explore the performance of inhaled products in line with quality by design (QbD) (6). At the same time, these units also make it straightforward to test under the conditions specified for pMDIs with add-on devices through the provision of specially developed adapters and filter holders.

To meet the requirement for a time delay between actuation of the device and the start of APSD measurement, a timer-controlled, fast-acting, two-way solenoid valve provides a simple, cost-effective solution. Products, such as the breath-actuated controller BAC 2000 (Copley Scientific), provide near instantaneous starting and stopping of the air flow during testing and have both delay and inhaled time functions (7). Such products streamline testing in line with the new draft chapter, easing the task of gathering the information required to ensure the safety and efficacy of using pMDIs with add-on devices.

**References**